Effect of rs3910105 in the Synuclein Gene on Dopamine Transporter Availability in Healthy Subjects

키워드

참고문헌 (34)

1. Spillantini MG, "alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies", Proc Natl Acad Sci U S A, 95, pp.6469~6473 (1998)[DOI]
2. Politis M, "Neuroimaging in Parkinson disease: from research setting to clinical practice", Nat Rev Neurol, 10, pp.708~722 (2014)[DOI]
3. Park E, "A new era of clinical dopamine transporter imaging using 123I-FP-CIT", J Nucl Med Technol, 40, pp.222~228 (2012)[DOI]
4. Booth TC, "The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1", AJNR Am J Neuroradiol, 36, pp.229~235 (2015)[DOI]
5. Marshall V, "Role of dopamine transporter imaging in routine clinical practice", Mov Disord, 18, pp.1415~1423 (2003)[DOI]
6. Zipursky RB, "PET and SPECT imaging in psychiatric disorders", Can J Psychiatry, 52, pp.146~157 (2007)[DOI]
7. Thomas AJ, "Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB", Neurology, 88, pp.276~283 (2017)[DOI]
8. FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls, "Eur J Nucl Med Mol Imaging", 2014, 1938~1946, 10.1007[DOI]
9. Stefanis L, "<TEX>${\alpha}$<", TEX>-Synuclein in Parkinson's disease, 2012, pp.2, a009399~
10. Beyer K, "Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers", Acta Neuropathol, 112, pp.237~251 (2006)[DOI]
11. Bisaglia M, "Structural insights on physiological functions and pathological effects of alpha-synuclein", FASEB J, 23, pp.329~340 (2009)[DOI]
12. Sidhu A, "alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease", FEBS Lett, 565, pp.1~5 (2004)[DOI]
13. Perez RG, "A role for alpha-synuclein in the regulation of dopamine biosynthesis", J Neurosci, 22, pp.3090~3099 (2002)[DOI]
14. Spillantini MG, "The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy", Ann N Y Acad Sci, 920, pp.16~27 (2000)
15. Braak H, "Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)", J Neurol, 249(Suppl 3), pp.III (2002), 1~III[DOI]
16. Mollenhauer B, "<TEX>${\alpha}$<", TEX>-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, 2011, pp.10, 230~240
17. Beyer K, "Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases", Neurogenetics, 9, pp.15~23 (2008)[DOI]
18. Gao R, "CSF biomarkers and its associations with 18F-AV133 cerebral VMAT2 binding in Parkinson's disease-a preliminary report", PLoS One, 11, pp.e0164762~ (2016)[DOI]
19. Spillantini MG, "Alpha-synuclein in Lewy bodies", Nature, 388, pp.839~840 (1997)[DOI]
20. Edwards TL, "Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease", Ann Hum Genet, 74, pp.97~109 (2010)[DOI]
21. Parkinson Progression Marker Initiative, "The Parkinson Progression Marker Initiative (PPMI)", Prog Neurobiol, 95, pp.629~635 (2011)[DOI]
22. Garcia-Gomez FJ, "Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane", Rev Esp Med Nucl Imagen Mol, 32, pp.350~356 (2013)
23. Tzourio-Mazoyer N, "Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain", Neuroimage, 15, pp.273~289 (2002)[DOI]
24. Mollenhauer B, "Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls", Neurology, 89, pp.1959~1969 (2017)[DOI]
25. Heckman MG, "Parkinson's disease susceptibility variants and severity of Lewy body pathology", Parkinsonism Relat Disord, 44, pp.79~84 (2017)[DOI]
26. Caspell-Garcia C, "Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease", PLoS One, 12, pp.e0175674~ (2017)[DOI]
27. Chen PS, "Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers--a SPECT study", Neuroimage, 56, pp.1526~1530 (2011)[DOI]
28. van de Giessen E, "Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3", J Nucl Med, 50, pp.45~52 (2009)
29. van Dyck CH, "Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene", J Nucl Med, 46, pp.745~751 (2005)
30. Fazio L, "D2 receptor genotype and striatal dopamine signaling predict motor cortical activity and behavior in humans", Neuroimage, 54, pp.2915~2921 (2011)[DOI]
31. Locascio JJ, "Association between <TEX>${\alpha}$<", TEX>-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease, 2015, pp.138, 2659~2671
32. Emamzadeh FN, "Alpha-synuclein structure, functions, and interactions", J Res Med Sci, 21, pp.29~ (2016)[DOI]
33. Wong YC, "<TEX>${\alpha}$<", TEX>-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies, 2017, pp.23, 1~13
34. Rhinn H, "Alternative <TEX>${\alpha}$<", TEX>-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology, 2012, pp.3, 1084~

관련 논문AI추천